4D Molecular Therapeutics Inc. (NASDAQ:FDMT)’s traded shares stood at 2.07 million during the last session. At the close of trading, the stock’s price was $17.20, to imply a decrease of -6.32% or -$1.16 in intraday trading. The FDMT share’s 52-week high remains $26.49, putting it -54.01% down since that peak but still an impressive 69.07% since price per share fell to its 52-week low of $5.32. The company has a valuation of $576.20M, with an average of 0.6 million shares in intraday trading volume over the past 10 days and average of 320.11K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for 4D Molecular Therapeutics Inc. (FDMT), translating to a mean rating of 1.90. Of 7 analyst(s) looking at the stock, 0 analyst(s) give FDMT a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.79.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
4D Molecular Therapeutics Inc. (NASDAQ:FDMT) trade information
After registering a -6.32% downside in the last session, 4D Molecular Therapeutics Inc. (FDMT) has traded red over the past five days. The stock hit a weekly high of 19.18 this Friday, 03/17/23, dropping -6.32% in its intraday price action. The 5-day price performance for the stock is 11.33%, and -6.88% over 30 days. With these gigs, the year-to-date price performance is -22.56%. Short interest in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) saw shorts transact 2.17 million shares and set a 8.26 days time to cover.
Analysts on Wall Street suggest a consensus price target of $38.14, implying an increase of 54.9% to the stock’s current value. The extremes give us $14.00 and $70.00 for target low and target high price respectively. As such, FDMT has been trading -306.98% off suggested target high and 18.6% from its likely low.
4D Molecular Therapeutics Inc. (FDMT) estimates and forecasts
Looking at statistics comparing 4D Molecular Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. 4D Molecular Therapeutics Inc. (FDMT) shares are 86.15% up over the last 6 months, with its year-to-date growth rate lower than industry average at -3.31% against 10.80%. Revenue is forecast to grow 7.10% this quarter before falling -11.00% for the next one. The rating firms project that company’s revenue will shrink -75.60% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is $3 million. Meanwhile, for the quarter ending Mar 2023, a total of 3 analyst(s) estimate revenue growth to $1.27 million.Earnings reports from the last fiscal year show that sales brought in $92k and $1.22 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 3,160.90% before jumping 4.20% in the following quarter.
FDMT Dividends
4D Molecular Therapeutics Inc. has its next earnings report out between March 27 and March 31. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. 4D Molecular Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
4D Molecular Therapeutics Inc. (NASDAQ:FDMT)’s Major holders
4D Molecular Therapeutics Inc. insiders hold 11.52% of total outstanding shares, with institutional holders owning 83.04% of the shares at 93.85% float percentage. In total, 83.04% institutions holds shares in the company, led by BVF Inc. As of Sep 29, 2022, the company held over 4.01 million shares (or 12.37% of shares), all amounting to roughly $32.22 million.
The next major institution holding the largest number of shares is Viking Global Investors, L.P. with 3.94 million shares, or about 12.16% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $31.66 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the 4D Molecular Therapeutics Inc. (FDMT) shares. Going by data provided on Sep 29, 2022, Vanguard Total Stock Market Index Fund holds roughly 0.81 million shares. This is just over 2.50% of the total shares, with a market valuation of $6.5 million. Data from the same date shows that the other fund manager holds a little less at 0.68 million, or 2.10% of the shares, all valued at about 15.12 million.
